The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Now, if ever there ...

The NCCN’s updated guidelines for the treatment of breast cancer include updates on sentinel lymph node biopsy, ovarian function suppression, and the use of prognostic tools.

One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. For many, the diagnosis doesn’t end there — up to 30 percent of early-stage breast cancer cases will later ...

Hormone therapy for ER-positive/HER2-negative metastatic breast cancer involves CDK4/6 inhibitors and aromatase inhibitors or fulvestrant to control disease ...

After you’re diagnosed with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer, your doctor’s goal is to build a treatment plan that gives you the best chance of controlling your ...

When you get an HR+/HER2- metastatic breast cancer (MBC) diagnosis, it can feel like your future is out of your hands. Treatment for this type of cancer targets certain receptors on cancer cells, and ...

Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...

Updated NCCN Clinical Practice Guidelines in Oncology now recognize that MammaPrint and BluePrint testing can help identify a ...

This symposium took place during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The aim ...